{'fraction_non_alphanumeric': 0.017085427135678392, 'fraction_numerical': 0.0010050251256281408, 'mean_word_length': 5.5927152317880795, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[The latest progestagens].


 Although there is no epidemiologic proof, combined oral contraceptives (OCs) containing the derivatives of third generation progestins seem to bring patients better likelihood of favorable long-term performance and reduced risk of vascular events. These third generation progestins include desogestrel, gestodene, and norgestimate. Health workers must remember that this risk was no longer the same as that of the first statistics of the Royal College of General Practitioners which made one afraid of even the OCs with lower levels of ethinyl estradiol and first and second generation progestins. In either case, numerous studies proved the excellent clinical tolerance and acceptability of third generation progestins by patients. By reason of these qualities, women over 40 can probably continue to use them except if they have contraindications related to a personal or genetic condition. On the other hand, an already observed comparison has occurred between the third generation progestins, no matter whether they originated from progesterone or derivatives of nortestosterone. The first generation progestins were considered as exercising a progestenic and estrogen agonist effect and having excellent metabolic tolerance. While the second generation progestins were appreciated for their anti-gonadotropic properties and anti-estrogenic powers, their adverse metabolic effects were feared. Today, the latest norpregnane derivatives are also endowed with powerful anti-gonadotropic capacities whereas the recent derivatives of nortestosterone have lost a very big part of their metabolic weaknesses. Improvement of the lipid profile that they determine, in association with ethinyl estradiol, can bring hope that recent OCs can even contribute to the improvement of the arterial condition, at least in certain women. For example, women with a history of thromboembolism may be able to use the norpregnane derivatives, which are still under development.
